News Search Results
Jul 29, 2025, 02:00 ET Kinvard Bio Secures Follow-on CARB-X Funding to Accelerate Development of Next-Generation Antibiotics
RALEIGH, N.C., July 29, 2025 /PRNewswire/ -- Kinvard Bio Inc., a biotechnology company pioneering a next-generation class of broad-spectrum antibiotics, today announced it has been awarded US$2.7 million
More news about: Kinvard Bio Inc
Jul 28, 2025, 21:42 ET Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
July 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 11, 2025,
More news about: Heron Therapeutics, Inc.
Jul 28, 2025, 17:31 ET Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight
dopaminergic drugs, primarily address motor symptoms but fail to halt disease progression. This unmet medical need is pushing pharmaceutical and biotechnology companies to focus on alpha-synuclein inhibitors, which target the underlying pathology by preventing protein misfolding, aggregation, and
More news about: DelveInsight Business Research, LLP
Jul 28, 2025, 17:00 ET RCKT INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
than Monday, August 11, 2025. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit
More news about: Robbins Geller Rudman & Dowd LLP
Jul 28, 2025, 12:44 ET Rubin and Rudman Receives Empowering Women Award from Massachusetts Lawyers Weekly for Third Consecutive Year
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Jul 28, 2025, 09:10 ET XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury
neural progenitor cells and analyzing their potential therapeutic effects on patients with spinal cord injury (SCI). XellSmart is a leading biotechnology company dedicated to developing innovative iPSC-derived cell therapies. To date, the company has secured seven Investigational New Drug (IND) approvals
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Jul 28, 2025, 08:42 ET Robles BioCeutics Signs Manufacturing Partnership Agreement with Innovigen to Accelerate Production of Regenerative Skincare Line
criteria. In addition, the companies will explore co-development opportunities for next-generation skincare products rooted in regenerative science and biotechnology. Both parties have agreed to maintain strict confidentiality and protect proprietary information throughout this collaboration and in any future
More news about: Robles BioCeutics
Jul 28, 2025, 08:30 ET 5 Critical Questions to Ask Before Applying AI to Real-World Data, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jul 28, 2025, 08:28 ET World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market
new chapter for home-use professional-grade bioactive solutions. About ImmVira ImmVira is a global leading clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization
More news about: ImmVira
Jul 28, 2025, 08:00 ET Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from retinal degenerative
More news about: Nanoscope Therapeutics
Jul 28, 2025, 06:00 ET Blue Water Acquisition Corp. III Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing July 31, 2025
business, industry, sector or geographical location, the Company intends to focus on high-potential companies in the artificial intelligence (AI), biotechnology, healthcare and technology sectors. Forward-Looking Statements This press release contains statements that constitute "forward-looking
More news about: Blue Water Acquisition Corp iii
Jul 27, 2025, 20:15 ET Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30
patent protection until 2044 without patent extensions. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Jul 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers - FTRE
global contract research organization ("CRO") that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. The Company claims to have the "scale and expertise to advise, design and deliver [its] customers' programs, projects
More news about: Pomerantz LLP
Jul 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Jul 27, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Jul 25, 2025, 13:26 ET CS Analytical Expands Service Offering With Launch of Gas Testing Analytical
infrastructure, Gas Testing Analytical will deliver specialized testing, sampling, and validation services for gases and utilities used in pharmaceutical, biotechnology, and medical device manufacturing CLIFTON, N.J.,
More news about: CS Analytical
Jul 25, 2025, 12:13 ET Proteomics Market to Expand Rapidly, with 13% CAGR forecast Through 2030
the market's future.Emerging startup: Alamar Biosciences Nautilus Biotechnology Pixelgen Technologies Syncell Inc. SengenicsThe report addresses the following
More news about: BCC Research LLC
Jul 25, 2025, 09:32 ET Data Center Infrastructure Market Experiences Growth of 10.20 billion by 2031 at CAGR of 16.1% | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Jul 25, 2025, 09:07 ET Spear Bio Launches Next Generation Ultrasensitive Immunoassay Solution SPEAR UltraDetect™ to Transform Neurodegenerative Disease Research
WOBURN, Mass., July 25, 2025 /PRNewswire/ -- Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, today announced the commercial launch of its SPEAR UltraDetect™ immunoassay
More news about: Spear Bio
Jul 25, 2025, 08:49 ET Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 25, 2025, 06:27 ET Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 24, 2025, 21:00 ET Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
we will deliver paradigm-shifting treatments to patients across the globe." Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address unmet medical needs in oncology, autoimmune,
More news about: Leads Biolabs
Jul 24, 2025, 18:32 ET WesternU COMP-Northwest to be named Heatherington College of Osteopathic Medicine
Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Jul 24, 2025, 10:00 ET Lilly confirms date and conference call for second-quarter 2025 financial results announcement
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jul 24, 2025, 10:00 ET Healthcare Consulting Services Market is expected to generate a revenue of USD 27.3 Billion by 2032, Globally, at 7.3% CAGR: Verified Market Research®
By Application (Pharmaceutical and Biotech Companies, Chemical Industries, Private Biobanks), By End-User Industry (Healthcare, Pharmaceuticals, Biotechnology, Academic and Research Institutions, Food and Beverage), By Geography, And Forecast
More news about: Verified Market Research